Intellia Therapeutics - NTLA Stock Forecast, Price & News

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research report on Friday, August 5th. Oppenheimer cut their price objective on Intellia Therapeutics from $160.00 to $130.00 in a research note on Monday, May 9th. Bank of America began coverage on Intellia Therapeutics in a research report on Thursday, June 16th. They issued a "buy" rating and a $70.00 target price on the stock. SVB Leerink dropped their price target on Intellia Therapeutics from $155.00 to $152.00 and set an "outperform" rating for the company in a research report on Friday, August 5th. Finally, The Goldman Sachs Group decreased their price objective on Intellia Therapeutics from $206.00 to $180.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $128.00.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $67.74 on Friday. The company's 50-day moving average is $57.34 and its two-hundred day moving average is $63.39. The firm has a market capitalization of $5.15 billion, a price-to-earnings ratio of -12.66 and a beta of 2.00. Intellia Therapeutics has a 1-year low of $37.08 and a 1-year high of $180.59.

Intellia Therapeutics (NASDAQ:NTLA - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.03). The business had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. Intellia Therapeutics had a negative net margin of 883.17% and a negative return on equity of 40.23%. The company's revenue was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.01) earnings per share. As a group, equities analysts anticipate that Intellia Therapeutics will post -5.83 earnings per share for the current fiscal year.